

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## ASCENTAGE PHARMA GROUP INTERNATIONAL

亞盛醫藥集團

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6855)**

### VOLUNTARY ANNOUNCEMENT

## ASCENTAGE PHARMA'S GLOBAL INDUSTRIAL BASE HAS OBTAINED A PRODUCTION LICENSE

Ascentage Pharma Group International (the “Company” or “Ascentage Pharma”) is pleased to announce that the Company recently passed the on-site inspection and was approved to be issued a drug production enterprise license (Certificate A). This certificate is the first certificate A drug production license obtained by a biopharmaceutical company in Suzhou in 2022, and it is also the first certificate A drug production license obtained since the establishment of the Jiangsu Provincial Food and Drug Administration Inspection Center, Suzhou Branch.

The industrial base is refined in accordance with the cGMP requirements of Europe, the U.S. and China, and it also implements quality management in accordance with such requirements. Obtaining the approval of this certificate will support the Company to produce innovative drugs with global patents and global market potential in Suzhou, and supply drugs to the global market.

Ascentage Pharma's global industrial base is located in Ascentage Pharma's global headquarters park. The current annual production capacity of oral solid dosage forms is 250 million tablets or capsules, which can meet the production needs of clinical samples and commercialized drugs at different stages. The Company's blockbuster product Bcl-2 selective inhibitor APG-2575 tablet, which is undergoing key registration clinical trials, will conduct clinical sample production, registration batch and process verification batch production, and future commercial production at the industrial base.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will be able to obtain further approval for, or ultimately market APG-2575 successfully.

By order of the Board  
**Ascentage Pharma Group International**  
**Dr. Yang Dajun**  
*Chairman and Executive Director*

Suzhou, People's Republic of China, November 27, 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yang Dajun as Chairman and executive Director, Dr. Wang Shaomeng and Dr. Lu Simon Dazhong as non-executive Directors, and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.*